| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.36 | 0.04 (+3.43%) | 1.15 - 1.88 | 5.5 thousand (Below Avg) |
Market data as of 3:55PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 1.37 |
|---|---|
| Previous Close | 1.31 |
| Day's Range | 1.31 - 1.37 |
| Market Cap | 17.1M |
| Avg Volume (10 Day) | 12.5K |
| Price/Earnings (Trailing 12 Mo.) | 14.6x |
| Earnings Per Share (Trailing 12 Mo.) | 0.09 |
| Dividend Yield | 0.02 (2.95%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for RELV
| RELV | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -5.72% | |
| Net Income Growth (1yr) | 33.24% | |
| Total Debt/Equity | 0.18 | |
| LT Debt/Equity | 0.15 | |
| Earnings Yield | 6.85% | |
| Price/Sales | 0.24 |
| Company | Last | Change |
|---|---|---|
| DARA BioSciences Inc | 0.76 | +7.04% |
| Ibio Inc | 0.42 | +10.85% |
| Merus Labs International Inc | 0.68 | +12.68% |
| Opexa Therapeutics Inc | 1.64 | -1.80% |
| China Botanic Pharmaceutical Inc | 0.55 | 0.00% |
Data is delayed by at least 15 min.